Status:
RECRUITING
Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy
Lead Sponsor:
Armed Forces Hospital, Pakistan
Conditions:
Hypoxic Ischemic Encephalopathy of Newborn
Eligibility:
All Genders
1-30 years
Phase:
PHASE1
Brief Summary
Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed co...
Detailed Description
A number of treatment modalities are available but are not clinically effective due to inefficacy and undesirable side effects. Despite therapeutic hypothermia being the sole effective neuroprotector ...
Eligibility Criteria
Inclusion
- all indoor newborn babies with HIE II and III
- who have not received therapeutic hypothermia
Exclusion
- grade I HIE
- Babies on TH
- babies whose parents do not give consent for inclusion in study
- babies with major congential malformations -
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06522581
Start Date
January 1 2024
End Date
January 1 2025
Last Update
August 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MH
Rawalpindi, Pakistan, 68000